Agrinnovation said Monday it raised $4 million in a round of funding led by Victor Smorgon Groupfrom Australia. Other investors include Yissum Research Development Company and theProvident Fund of the Employees of the Hebrew University of Jerusalem. Agrinnovation is an investment fund focused on agricultural inventions. The fund said a group of Chinese-Israeli investors will also likely invest, boosting total funding to $6 million.
HIPPY, or Home Instruction for Parents of Preschool Youngsters, is designed to help low-income parents prepare their 3- to 5-year-old children to start school. Parents receive a weekly curriculum. They are given books on a schedule — every week or every other week — including a new book that teaches them how to become their child’s first teacher.
The program was started in Israel in 1969 to help immigrants from North Africa and the Middle East prepare for life in their new country. HIPPY, which still operates in its native country, came to the United States in 1980 via the National Council for Jewish Women’s Research Institute for Innovation in Education at the Hebrew University of Jerusalem.
The Hebrew University of Jerusalem, Israel’s premier university and leading research institution, and the Fraunhofer Institute for Secure Information Technology SIT, the leading institute for applied cybersecurity research in Germany, agreed to jointly create a Fraunhofer Project Center for Cybersecurity in Jerusalem. The planned center is meant to become the leading institution for applied cybersecurity research in Israel, as well as worldwide.
A patented, highly efficient and environmentally responsible nanoparticle synthesis process enables the unique properties of AgCite inks. The process is licensed through inks pioneer Professor Shlomo Magdassi and Yissum Research Development Company, the technology transfer company of the Hebrew University of Jerusalem. The nanoparticle synthesis process begins with a silver precursor raw material and allows for fine control of the size, shape and distribution of the silver nanoparticles in accordance with customers’ printing requirements. This nanoparticle synthesis process is critical to the types of nanoparticles and ink formulations that can be produced.
Nano Dimension, a leading printing electronics company in the area of 3D printing (TASE: NNDM, OTCQB: NNDMY), announced today that Nano Dimension Technologies, a fully owned subsidiary of Nano Dimension, has made its first sale of 3D printers and nano inks in India, totaling USD $250K. The transaction was completed by Vigilante Environmental Solutions, Nano Dimension's business developer in India.
Yissum's Avraham Pharma shows promising new data on the long way to finding cure.
Dana Gavish Fridman, VP of marketing, joins VOI's Simcha Gluck to talk about the Hebrew University's 'tech transfer' company.
Dana explains how her company works: collecting ideas and intellectual property from the professors and researchers at the Hebrew University in Jerusalem and then patenting, funding research and development, and monetizing them. Generating more than $2 billion in annual sales, it has developed 2,500 inventions — from cherry tomatoes to cancer drugs to Mobileye, Israel’s most profitable innovation so far — and has 9,000 patents. Dana talks about what it’s like to work with the country’s greatest minds, and shares some little-known facts about the role that Israel’s Chief Scientist plays on the innovation scene.
Results show positive trends in primary end point of delaying or preventing onset of Alzheimer’s diseaseFinal results expected in Q3 2016, following 3 years of treatment
The novel technology by Prof. Nissim Benvenisty utilizes stem cells as models for genetic disorders and enables large scale screening of small molecule drugs
Where science meets art meets a branding experience: a new coffee experience thanks to Prof. Shlomo Magdassi's printing invention.
The BioDesign: Medical Innovation program, a joint effort of the Hebrew University of Jerusalem and the Hadassah Medical Center, allowed Sharon to recruit top engineering and business students to help her develop an alternative technology.
“HoloDent is the first holography scanning device for intraoral 3D modeling, reducing the time it takes to get dentures from 30 days to 30 minutes, while making the treatment far more comfortable and precise for all patients,” said Amit Zilberstein, a BioDesign fellow and CEO of the HoloDent company.
Prof. Yaakov Nahmias and Prof. Nissim benvenisty of the Hebrew University's Faculy of Science persent breakthrough research that may be the future alternative to animal trials.
The Global Innovation Awards were established by leading Chinese management consulting firm Shengjing Group and are taking place in China, the U.S., Europe, Latin America and Israel. The Israel segment of the competition was led by internationally recognized VC firm JVP. JVP's local competition partners include global technology corporations with strong footholds in Israel such as EMC and Deutsche Telecom, leading Israeli academic institutions such as the Hebrew University'sTechnology Transfer Company Yissum and IDC Executive Education as well as international accounting firm PwC, the Herzog Fox & Neeman Law Firm (HFN) and media partners PR Newswire.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has entered into a definitive license and research agreement with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents for the development and commercialization of a topical nano-formulated version of AmiKet, pursuant to the parties' existing binding memorandum of understanding from March 2015.
Qlight was founded in 2009 on the basis of technology developed in Prof. Uri Banin's laboratory at the Hebrew University of Jerusalem and commercialized by Yissum Technology Transfer Company of the Hebrew University of Jerusalem. The company was associated with Merck from the beginning. Merck's chemical division already produces the materials on which high-end LCD screens are based. The first cooperation between the companies was in development of a new and improved screen using Qlight's nano-crystals, cooperation that included financial support for research in return for marketing rights to the final product.
Ripples Brings Customizable Latte Art To Your Local Coffee Shop using edible nanoinks invented by Prof. Shlomo Magdassi of the Hebrew University of Jerusalem.
Jerusalem, Israel, June 18, 2015 – Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that it had signed multiple research and licensing agreements in the area of advanced materials with ICL (NYSE and TASE: ICL), a global manufacturer of products based on specialty minerals that fulfill essential needs of the world’s growing population in the agriculture, processed food and engineered materials markets.
The expanded collaboration includes a research agreement involving work in the field of materials and 3D printing of Prof. Shlomo Magdassi, the Casali Institute of Applied Chemistry, the Institute of Chemistry and the Center for Nanoscience and Nanotechnology at the Hebrew University, as well as a research and license agreement for an invention in the field of solar energy by Dr. Lioz Etgar from the Institute of Chemistry at the Hebrew University.
The innovative projects by Fourth Year students now face further development by the teams with the gudance of Yissum, the University's Technology Transfer Co.
NEW YORK, June 10, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) announced today that it has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclosporine A. Cyclosporine A, when administered systemically (Sandimmune®, Neoral®), is an effective treatment for psoriasis, atopic dermatitis, pemphigus vulgaris and other severe inflammatory dermatoses.
Dr. Daniel Teper, the CEO of Immune Pharmaceuticals, commented: "Following our lead product candidate bertilimumab in bullous pemphigoid, we are excited to expand our immuno-dermatology portfolio with an innovative topical formulation of cyclosporine A. Additionally, we are further strengthening both our nanotechnology platform and our partnership with Yissum, which already includes NanomAbs®"
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that research underlying BL-9020, for the treatment of Type 1 diabetes, won the Hebrew University's prestigious Kaye Innovation Award.
The award was granted to Hebrew University immunologist Professor Ofer Mandelboim, who studied the function of a protein receptor called NKp46 in the development of Type 1 diabetes. Prof. Mandelboim showed that NKp46 present on Natural Killer cells has a critical role in the development of the disease in mice, and that inhibition of the receptor almost entirely prevented the development of diabetes. This groundbreaking research is the basis for BioLineRx’s BL-9020, a novel monoclonal antibody which targets the Natural Killer (NK) receptor NKp46 for the prevention and treatment of Type 1 diabetes.